Cirrhosis: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (→Complications: started Hepatorenal syndrome) |
imported>David E. Volk m (subpages) |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
'''Cirrhosis''' is a "liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules."<ref name="title">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?mode=&term=Liver+Cirrhosis |title=Liver cirrhosis |accessdate=2008-01-07 |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=National Library of Medicine |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> | '''Cirrhosis''' is a "liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules."<ref name="title">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?mode=&term=Liver+Cirrhosis |title=Liver cirrhosis |accessdate=2008-01-07 |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=National Library of Medicine |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> | ||
| Line 18: | Line 19: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 16:48, 21 January 2008
Cirrhosis is a "liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules."[1]
Complications
Ascites
Hepatic encephalopathy
Hepatorenal syndrome
Octreotide/Midodrine combined therapy can help according to a randomized controlled trial.[2]
Prognosis
MELD Score
The MELD Score can help predict mortality. An online calculator is available.
References
- ↑ Anonymous. Liver cirrhosis. National Library of Medicine. Retrieved on 2008-01-07.
- ↑ Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA (2007). "Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome". Dig. Dis. Sci. 52 (3): 742–8. DOI:10.1007/s10620-006-9312-0. PMID 17235705. Research Blogging.